MedMatrix Rx
Daily 340B Morning Briefing
The 340B program landscape remains dynamic with significant legal and policy developments. Froedtert Memorial Lutheran Hospital has filed a lawsuit against CVS Health alleging $18 million in 340B diversions. Meanwhile, CMS faces pressure from healthcare groups to reconsider its 2027 outpatient payment proposals, which include contentious 340B drug payment cuts. Additionally, the National Association of Specialty Pharmacy has submitted comments on CMS’s proposed changes to the 340B payment methodology. These events highlight ongoing tensions and potential shifts in 340B program administration and reimbursement.
EXECUTIVE SUMMARY
01
Froedtert Hospital sues CVS over 340B diversion.
Froedtert Memorial Lutheran Hospital alleges CVS Health diverted $18 million in 340B savings from 2020 to 2025.
Froedtert Memorial Lutheran Hospital alleges CVS Health diverted $18 million in 340B savings from 2020 to 2025.
Source: Becker’s Hospital Review
02
Healthcare groups urge CMS to reconsider 2027 outpatient rule.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw 340B payment cuts in the proposed 2027 outpatient rule.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw 340B payment cuts in the proposed 2027 outpatient rule.
Source: Becker’s Hospital Review
03
NASP comments on CMS’s proposed 340B payment changes.
NASP submitted comments on the CY 2027 HOPPS proposed rule, focusing on Medicare reimbursement for 340B-acquired drugs.
NASP submitted comments on the CY 2027 HOPPS proposed rule, focusing on Medicare reimbursement for 340B-acquired drugs.
Source: NASP
04
Court decertifies 11 clinics in 340B dispute.
A federal judge set aside 340B certifications for 11 clinics, siding with drugmakers on statutory requirements.
A federal judge set aside 340B certifications for 11 clinics, siding with drugmakers on statutory requirements.
Source: Becker’s Hospital Review
05
AHA warns CMS against repeating 340B history.
AHA urges CMS not to finalize proposals that would accelerate 340B payment clawbacks and cut drug reimbursement.
AHA urges CMS not to finalize proposals that would accelerate 340B payment clawbacks and cut drug reimbursement.
Source: Becker’s Hospital Review
06
HRSA launches 340B Rebate Model Pilot Program.
HRSA’s revised 340B Rebate Model Pilot will launch January 1, 2027, focusing on MFP drugs under the Inflation Reduction Act.
HRSA’s revised 340B Rebate Model Pilot will launch January 1, 2027, focusing on MFP drugs under the Inflation Reduction Act.
Source: Drug Channels
07
Hospital and health center groups intervene in AbbVie 340B suit.
A federal judge allowed 340B Health and others to intervene in AbbVie’s lawsuit challenging 340B program rules.
A federal judge allowed 340B Health and others to intervene in AbbVie’s lawsuit challenging 340B program rules.
Source: Becker’s Hospital Review
08
Site-neutral payment pressures health systems.
Valley Health CEO highlights concerns over site-neutral payments affecting outpatient capacity decisions.
Valley Health CEO highlights concerns over site-neutral payments affecting outpatient capacity decisions.
Source: Becker’s Hospital Review
09
AAMC and AHA push for 340B rule changes.
AAMC and AHA filed comments targeting CMS’s Medicare Drug Price Negotiation Program and Sen. Cassidy’s 340B draft.
AAMC and AHA filed comments targeting CMS’s Medicare Drug Price Negotiation Program and Sen. Cassidy’s 340B draft.
Source: Becker’s Hospital Review
10
The Elevance Health Companies, Inc. v. Senderra Rx Partners, LLC.
A new lawsuit filed in M.D. Fla. involving 340B program issues.
A new lawsuit filed in M.D. Fla. involving 340B program issues.
Source: CourtListener
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing legal and policy challenges in the 340B program indicate potential shifts in reimbursement and operational practices. Stakeholders must closely monitor these developments to understand their impact on drug pricing, access, and compliance. The pressure from healthcare groups and legal interventions suggest that significant changes could be on the horizon, affecting how hospitals and pharmacies manage their 340B programs.
Emerging risks.
- Hospitals face increased financial strain from potential 340B payment cuts and clawbacks.
- Legal disputes may disrupt 340B program operations and access to discounted drugs.
- Healthcare providers could encounter compliance challenges due to changing 340B regulations.
- Pharmacies involved in litigation risk reputational damage and financial penalties.
Emerging opportunities.
- Stakeholders can influence policy by participating in comment periods and advocacy efforts.
- Hospitals may explore alternative reimbursement models to mitigate financial impacts.
- Pharmacies can improve compliance systems to adapt to evolving 340B regulations.
- Healthcare groups can collaborate to strengthen their advocacy positions in legal disputes.
Key actions for providers.
- Monitor CMS’s response to comments on the 2027 outpatient rule for potential adjustments.
- Review and adjust 340B program compliance strategies in light of recent court rulings.
- Engage in advocacy efforts to influence 340B policy changes and protect program benefits.
- Prepare for the implementation of HRSA’s 340B Rebate Model Pilot Program in 2027.
TOP STORIES
Froedtert Hospital sues CVS over alleged 340B diversion.
Becker’s Hospital Review · August 31, 2026
- Froedtert alleges CVS diverted $18 million in 340B savings.
- The lawsuit names CVS Health, CaremarkPCS, and WellPartner as defendants.
- Froedtert claims CVS artificially lowered reimbursements for 340B drugs.
Healthcare groups urge CMS to reconsider 2027 outpatient rule.
Becker’s Hospital Review · August 31, 2026
- AHA, AAMC, and AMGA submitted comments against 340B payment cuts.
- Groups argue the proposed 2.4% payment update is insufficient.
- They oppose site-neutral payment expansion and new prior authorization.
NASP comments on CMS’s proposed 340B payment changes.
NASP · September 1, 2026
- NASP focuses on Medicare reimbursement for 340B-acquired drugs.
- Comments address operational and compliance considerations.
- NASP highlights implications for specialty pharmacy services.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
AHA warns CMS against repeating 340B history.
Becker’s Hospital Review · August 26, 2026
- AHA opposes accelerating 340B payment clawbacks.
- CMS’s proposal would increase hospital repayment rates sixfold.
- AHA warns of financial strain on over 500 hospitals.
HRSA launches 340B Rebate Model Pilot Program.
Drug Channels · August 25, 2026
- The pilot program launches on January 1, 2027.
- It focuses on MFP drugs under the Inflation Reduction Act.
- The program aims to address nonduplication issues between MFP and 340B prices.
AAMC and AHA push for 340B rule changes.
Becker’s Hospital Review · August 26, 2026
- AAMC targets CMS’s Medicare Drug Price Negotiation Program rule.
- AHA comments on Sen. Cassidy’s 340B Drug Pricing Integrity draft.
- Both groups seek changes to five key provisions.
STATE DEVELOPMENTS
Washington — Prohibition on 340B Contract Pharmacies Billing Medicaid
Washington State Health Care Authority · September 11, 2026
- Washington State’s Health Care Authority has clarified that contract pharmacies are not permitted to bill Medicaid for drugs purchased at 340B pricing, including both fee-for-service and managed care claims.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
| D.D.C. | COREWELL HEALTH WILLIAM BEAUMONT UNIVERSITY HOSPITAL v. KENNEDY [source] | September 3, 2026 |
| M.D. Fla. | The Elevance Health Companies, Inc. v. Senderra Rx Partners, LLC [source] | September 4, 2026 |
| N.D. Ill. | ASTRAZENECA PHARMACEUTICALS LP v. KWAME RAOUL, in his official capacity as ATTORNEY GENERAL of the STATE OF ILLINOIS [source] | August 14, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
Identified recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, including reactions, statements, op-eds, and advocacy positions from various organizations and platforms.
AHA Comments on Cassidy 340B Discussion Draft Legislation
American Hospital Association (AHA) · August 25, 2026
- Main theme: AHA’s response to proposed changes in 340B program legislation
- Stakeholder sentiment: AHA expresses concern that proposed changes could weaken 340B hospitals’ ability to serve patients and communities.
- Potential implications: Potential reduction in hospitals’ capacity to provide essential healthcare services.
- Credibility: AHA is a reputable organization representing nearly 5,000 member hospitals and health systems.
WHAT TO WATCH NEXT
- Monitor CMS’s response to the 2027 outpatient rule comments for potential policy adjustments. [source]
- Prepare for the HRSA 340B Rebate Model Pilot Program launching January 1, 2027. [source]
- Track ongoing litigation involving 340B program issues for potential impacts on policy and compliance. [source]
- Stay informed on CMS’s final decision regarding the 2027 outpatient payment proposals. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.